Pharmacology and anti-tumor activity of RWJ67657, a novel inhibitor of p38 mitogen activated protein kinase

Endocrine therapy resistance is a primary cause of clinical breast cancer treatment failure. The p38 mitogen activated protein kinase (MAPK) signaling pathway is known to promote ligand independent tumor growth and resistance to endocrine therapy. In this study, we investigated the therapeutic poten...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Antoon, James W, Bratton, Melyssa R, Guillot, Lori M, Wadsworth, Scott, Salvo, Virgilio A, Elliott, Steven, McLachlan, John A, Burow, Matthew E
Formato: Artigo
Idioma:Inglês
Publicado em: e-Century Publishing Corporation 2012
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3410584/
https://ncbi.nlm.nih.gov/pubmed/22860234
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados